4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any one of Claims 1 to 3.

5. The composition of Claim 4, which further comprises an agent selected from β_2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, and combinations thereof; wherein the crystalline form and the agent are formulated together or separately.

6. The composition of Claim 5, which comprises a β_2 adrenergic receptor agonist and a steroidal anti-inflammatory agent.

7. The compound of any one of Claims 1-3 in micronized form.

~~8. A process for preparing the crystalline freebase Form III of Claim 1, comprising contacting biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester with acetonitrile.~~

~~98~~. A process for purifying biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, comprising forming the compound of any one of Claims 1-3.

~~109~~. A compound as claimed in any one of Claims 1 to 3, for use in therapy.

~~1110~~. A compound as claimed in Claim ~~109~~, for use in the treatment of chronic obstructive pulmonary disease or asthma, or for producing bronchodilation.

~~1211~~. The use of a compound as claimed in any one of Claims 1 to 3, for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease or asthma, or for producing bronchodilation.